The latest announcement is out from Dimerix Limited ( (AU:DXB) ).
Dimerix Limited has updated its Securities Trading Policy to align with current listing rules, reflecting its ongoing commitment to regulatory compliance. This update comes as the company continues to advance its Phase 3 clinical asset in kidney disease, potentially impacting its market operations and stakeholder interests.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney and respiratory diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease. These products were identified using Dimerix’s proprietary Receptor Heteromer Investigation Technology (Receptor-HIT), a platform for understanding receptor interactions to identify new drug opportunities.
YTD Price Performance: 23.53%
Average Trading Volume: 2,068,801
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$234.9M
See more data about DXB stock on TipRanks’ Stock Analysis page.